Aptamers for use in inhibition and/or suppression of TLR9 activation
AssigneeBerlin Cures GmbH
InventorsAnnekathrin Haberland, Katrin Wenzel
Life of this patent
Estimating the term…
Abstract
The present invention relates to new aptamer molecules for use in therapy of a subject by inhibiting or suppressing the activation of TLR9 in a cell, a method of inhibiting or suppressing the activation of TLR9 in a cell using such aptamer molecules, a pharmaceutical composition and a kit comprising such aptamer molecules and the use of aptamer molecules for inhibiting or suppressing TLR9 activation.
Claims21
A method of treating a disease or disorder characterized by overexpression and/or overactivity of TLR9-mediated signaling in a subject, comprising administering to a mammalian subject in need an effective amount of an aptamer to inhibit activation of TLR9 in a cell of the subject, wherein the aptamer has a nucleic acid sequence of SEQ ID No.:1 (GGT TGG TGT GGT TGG) and/or a nucleic acid sequence being at least 80% identical to SEQ ID No.:1, and wherein the aptamer interacts specifically with the TLR 9 receptor to inhibit activation of TLR9 in the cell of the subject.
A method of inhibiting or suppressing activation of TLR9 in a cell comprising contacting a mammalian cell expressing TLR9 with an effective amount of an aptamer, wherein the method is carried out in vitro/ex vivo and wherein the aptamer has a nucleic acid sequence of SEQ ID No.:1 (GGT TGG TGT GGT TGG) and/or a nucleic acid sequence being at least 80% identical to SEQ ID No.:1, and wherein the aptamer interacts specifically with the TLR 9 receptor to inhibit activation of TLR9 in the cell of the subject.
Dependencies are inferred from the claim text.